Table 3

Overall comparison of the frequency of patients with autoimmune diseases

Proportion (%) of patients receiving

co-therapies


Before rituximab

During rituximab

After rituximab during follow-upa


Immunosuppressives

98.1

41.2

78.6

Prednisolone

68.9

66.1

58.9

with glucocorticoid bolus therapy

17.0

1.25

1.6

Methylprednisolone

25.4

13.2

4.3

Methotrexate

22.1

6.9

8.9

Cyclophosphamide

36.2

8.15

3.2

Azathioprine

38.1

11.9

10.8

Mycophenolate mofetil

27.6

15.0

17.8

Intravenous Ig

17.0

3.4

5.1

Plasmapheresis

13.8

3.4

0.8

Other immunosuppressives

16.0

5.3

5.4


Overall comparison of the frequency of patients with autoimmune diseases receiving at least one administration of different types of therapies before, during and after rituximab therapy. Note, that certain immunosuppressive drugs were substantially different between individual diseases and only frequencies above 10% have been considered for this comparison.

aFollow-up was as defined and recorded by the investigating physician.

Tony et al. Arthritis Research & Therapy 2011 13:R75   doi:10.1186/ar3337

Open Data